Navigation Links
S*BIO to Initiate Global Phase 3 Clinical Trials of its Novel JAK2 Inhibitor Pacritinib for Treatment of Myelofibrosis (MF)
Date:10/25/2011

mutation.

About S*BIO Pte LtdS*BIO is a privately-held biotech company focused on the clinical development of novel targeted small molecule drugs for the treatment of cancer with leading programs including kinases and histone deacetylases (HDAC). Pacritinib, or SB1518, S*BIO's potent and orally-active JAK2 inhibitor, entered the clinic in 2008 and has completed Phase 2 trials for MF.  It has received orphan drug designation from the U.S. and the E.U. regulatory authorities. S*BIO's lead HDAC inhibitor, pracinostat (SB939), is currently in Phase 2 trials. S*BIO's SB1317, a novel multikinase inhibitor, is in Phase 1 trials and under a worldwide exclusive license with Tragara Pharmaceuticals, Inc. for its development and commercialization.

S*BIO has strong links with a network of medical oncologists in Asia Pacific and its investors include Bio*One Capital a subsidiary of EDBI (EDB Investments), Aravis Ventures, Mitsui Ventures, Novartis Bioventures and other international funds. More information about S*BIO can be found at www.sbio.com.S*BIO Pte Ltd:Russo PartnersTamar Howson

Tony Russo +1 212-845-4251Interim CEO & Board Member

Tony.Russo@russopartnersllc.comtamarhowson@me.com

Andreas Marathovouniotis +1 212-845-4235Andreas.Marathis@russopartnersllc.com
'/>"/>

SOURCE S*BIO Pte Ltd
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Additional Data From Multiple Phase 1 and 2 Studies of S*BIOs Novel JAK2 Inhibitor SB1518 Demonstrate Safety and Efficacy for Treatment of Symptomatic Myelofibrosis (MF)
2. S*BIO Restructures Agreement With Onyx for JAK2 Inhibitor Program
3. S*BIOs Novel Dual mTOR/PI3 Kinase Inhibitor SB2343 Demonstrates Excellent PK/PD Properties Leading to Significant Anti-Tumor Efficacy in Xenograft Models
4. S*BIOs JAK2 Inhibitor SB1518 Granted Orphan Drug Designation by European Commission (EC) for the Treatment of Myelofibrosis (MF)
5. S*BIO Advances JAK2 Inhibitor SB1518 into Phase 1/2 Clinical Trial in Australia for the Treatment of Chronic Idiopathic Myelofibrosis
6. S*BIO Initiates U.S. Phase I Clinical Trials of Oral JAK2 Inhibitor SB1518 for the Treatment of Hematological Malignancies
7. S*BIO to Develop New JAK-2 Inhibitor for Treatment of Myeloproliferative Disorders and Hematological Malignancies
8. Elusys Initiates Third Clinical Safety Study of Anthim, a New Anthrax Treatment; Company Successfully Completes Manufacturing at Commercial Scale
9. CryoLife Initiates Enrollment in U.S. Clinical Trial for BioFoam®
10. CareFusion Initiates Class I Recall of EnVe Ventilators
11. Takeda Initiates Phase 3 Clinical Trial Program in the United States, Latin America, and Europe for Investigational Type 2 Diabetes Therapy TAK-875
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... , May 21, 2013 Abaxis, Inc. ... analysis systems, announced today that Martin Mulroy ... the Stifel Annual Dental & Veterinary Conference on Wednesday, ... will be held at Le Parker Meridien Hotel in ... About Abaxis Abaxis develops, manufactures, markets and ...
(Date:5/21/2013)... , May 21, 2013 ... report is available in its catalogue: ... and Reimbursement Scenario for Medical Devices in ...   Changing Regulatory ... the US Market   ...
(Date:5/21/2013)... 21, 2013 STAAR Surgical Company (NASDAQ: ... of minimally invasive ophthalmic products, today announced that it ... the Company,s recent financial results and business developments with ... present at the 38 th Annual Deutsche Bank ... at the Westin Waterfront Hotel on Wednesday, May 29, ...
Breaking Medicine Technology:Abaxis, Inc. to Present at the Stifel Annual Dental & Veterinary Conference 2Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market 2Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market 3Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market 4STAAR Surgical To Present At Upcoming Investor Conferences 2
(Date:5/21/2013)... Primary care practice transformation on a large ... reform efforts aimed at achieving better outcomes, better ... evidence that transformation toward the patient-centered medical home ... care environment, the U.S. Department of Health and ... funded 14 studies to learn more about the ...
(Date:5/21/2013)... May 21, 2013 HealthSmart continues to ... national presence has required the hiring of new talent ... is pleased to announce that Dawn Powell has joined ... as the Director of Account Management in the Central ... in Irving, Texas. With extensive client management, employee benefits, ...
(Date:5/21/2013)... According to a May 13, 2013 New Zealand Herald ... Botox injections have become the most popular cosmetic procedure ... goo.gl/8iYbD). Although it is mostly associated with women, Botox ... facial wrinkles less visible by paralyzing facial muscles. The effects ... This means that people who are conscious about their looks ...
(Date:5/21/2013)... CA (PRWEB) May 21, 2013 Global ... organization, and Bodybuilding.com, the largest online retailer of health ... a new reality-based sports show, Warrior Island. “We ... on; YouTube, Facebook & Twitter, with our unique social ... Island maroons these elite fighters on an island in ...
(Date:5/21/2013)... Research into genetic features of pulmonary fibrosis by ... of Medicine may lead to improved treatment of this ... by JAMA . , The study found that ... cases of pulmonary fibrosis, a chronic progressive disease with ... of the study, researchers may want to consider including ...
Breaking Medicine News(10 mins):Health News:AHRQ-funded journal supplement offers lessons on primary care practice transformation 2Health News:AHRQ-funded journal supplement offers lessons on primary care practice transformation 3Health News:AHRQ-funded journal supplement offers lessons on primary care practice transformation 4Health News:AHRQ-funded journal supplement offers lessons on primary care practice transformation 5Health News:AHRQ-funded journal supplement offers lessons on primary care practice transformation 6Health News:New Talent Joins the HealthSmart Account Management Team 2Health News:Botox – Is the World’s Most Popular Cosmetic Procedure Safe? 2Health News:Bodybuilding.com Partners with Global Proving Ground’s New Reality Show Warrior Island 2Health News:Bodybuilding.com Partners with Global Proving Ground’s New Reality Show Warrior Island 3Health News:Researchers find genetic tie to improved survival time for pulmonary fibrosis 2
... Medical College at Dallas report that contact lenses, ... transmissible materials are expected to reduce the possibility ... are available now. Based in part on these ... approved hyper-oxygen transmissible contact lenses for 30-day continuous ...
... offers the hope of a less painful technique than traditional ... into an artery to bypass a blockage in the heart ... redirecting traffic. The blood is sent to the heart muscle ... ,Dr Stephen Oesterle, the author of a report into the ...
... has been experimented that can suppress menstruation for as long ... years.The tablet, which blocks the action of the hormone progesterone, ... the monthly menstrual cycle. Two versions of the new pill ... results published by American and German scientists in the latest ...
... for persons suffering from types of hereditary cancers.The Imperial ... allow doctors to identify people likely to suffer from ... ,By looking at skin warts, benign growths ... a history of HNPCC //- hereditary non-polyposis colorectal cancer ...
... detect cervical cancer,has been developed by Australians which may replace ... UK, Italy, Spain as well as Australia. ,Sydney-based Polartechnics ... CSIRO and claims that it offers instant results and greater ... probe to collect information directly from the cervix about the ...
... see couples who are HIV sero discordant but who would like ... and the wife is negative and they are planning to have ... in 500 risk of transmitting the virus to the female partner ... Sperm washing is a risk-reduction option in which ...
Cached Medicine News:Health News:New contact lens materials 2Health News:Revolution in surgery 2Health News:Pause as you please 2Health News:Sperm washing helps couples 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: